Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.

Battistello E, Katanayeva N, Dheilly E, Tavernari D, Donaldson MC, Bonsignore L, Thome M, Christie AL, Murakami MA, Michielin O, Ciriello G, Zoete V, Oricchio E.

Blood. 2018 May 24;131(21):2345-2356. doi: 10.1182/blood-2017-10-809210. Epub 2018 Mar 22.

2.

Inhibition of A2A Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455.

Gessi S, Bencivenni S, Battistello E, Vincenzi F, Colotta V, Catarzi D, Varano F, Merighi S, Borea PA, Varani K.

Front Pharmacol. 2017 Dec 1;8:888. doi: 10.3389/fphar.2017.00888. eCollection 2017.

3.

Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies.

Mina M, Raynaud F, Tavernari D, Battistello E, Sungalee S, Saghafinia S, Laessle T, Sanchez-Vega F, Schultz N, Oricchio E, Ciriello G.

Cancer Cell. 2017 Aug 14;32(2):155-168.e6. doi: 10.1016/j.ccell.2017.06.010. Epub 2017 Jul 27.

4.

Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma.

Oricchio E, Katanayeva N, Donaldson MC, Sungalee S, Pasion JP, B├ęguelin W, Battistello E, Sanghvi VR, Jiang M, Jiang Y, Teater M, Parmigiani A, Budanov AV, Chan FC, Shah SP, Kridel R, Melnick AM, Ciriello G, Wendel HG.

Sci Transl Med. 2017 Jun 28;9(396). pii: eaak9969. doi: 10.1126/scitranslmed.aak9969.

Supplemental Content

Loading ...
Support Center